Editas Medicine

The Gene Switch Market is projected to grow from USD 0.78 Bn in 2024 to USD 1.78 Bn by 2031, with a CAGR of 11.6%. CoherentMI's report provides a comprehensive analysis of market trends, competitive landscape, and key players like Novartis, Pfizer, and Gilead Sciences.

DelveInsight's 'Hematopoietic Stem Cell Transplantation Pipeline Insight, 2024' report details 20+ companies developing therapies, including Orchard Therapeutics, Lisata Therapeutics, Genenta science, and Editas Medicine. Key therapies in clinical trials are OTL-204, OTL-105, LSTA201, Temferon, and EDIT-301. The report covers mechanism of action, route of administration, and market dynamics.

The Cas nuclease market is forecasted to grow from $2.75 billion in 2023 to $6.56 billion by 2028 at a CAGR of 19.0%, driven by advancements in genome editing, increased biotechnology funding, and demand for personalized medicine.

Beam Therapeutics acknowledges a patient death in a Phase 1/2 trial for sickle cell disease, attributing it to pre-conditioning, not the base-editing treatment. AstraZeneca, UT, and LIVESTRONG report successful therapeutic genome editing in mouse liver via lipid nanoparticles. Korean researchers find base and prime editors produce fewer large DNA deletions than Cas9 nucleases. YolTech demonstrates effective mRNA delivery to bone marrow cells for blood disorder treatment. Japanese scientists develop a curative strategy for congenital purpura fulminans using engineered APC. US-France team identifies key host factors enhancing rotavirus vaccine production. Allogene Therapeutics shares positive Phase 1 data for renal cell carcinoma treatment. Cellectis presents strategies to enhance CAR T-cell efficacy in solid tumors. Caszyme and Integra Therapeutics enter a licensing agreement for safer gene therapies. Industry updates include financial results and clinical trial progress from various companies. CRISPR genome engineering symposium to feature latest advancements. CRISPR gene editing can integrate mitochondrial DNA into the nuclear genome, but exonucleases can mitigate this. HuidaGene Therapeutics' CRISPR-Cas13 RNA-editing therapy for macular degeneration is accepted by the FDA.

The Global Sickle Cell Disease (SCD) Market is projected to grow from USD 2.40 billion in 2023 to USD 12.38 billion by 2032, driven by advancements in gene therapy, including CRISPR, and increased investment in research. North America leads the market, with significant contributions from pharmaceutical companies and research institutions. Challenges include high treatment costs and limited healthcare infrastructure in low-income regions. Opportunities lie in expanding clinical trials, enhancing patient care, and developing cost-effective treatments.

Save time by focusing on key insights.

The hemoglobinopathies treatment market is projected to grow from $8.2 billion in 2023 to $13.2 billion by 2028, driven by genetic inheritance, advancements in cell-based gene therapies, and personalized medicine. Key players include Pfizer, Sanofi, and Vertex Pharmaceuticals.

The global gene synthesis market, valued at USD 1.66 billion in 2023, is projected to grow at a CAGR of 22.74% to USD 10.5 billion by 2032, driven by advancements in synthetic biology, personalized medicine, and biopharmaceutical production. Key players like Thermo Fisher Scientific and GenScript are expanding services, with CRISPR and synthetic biology driving demand. Challenges include high costs, regulatory issues, and technical difficulties in long-sequence synthesis. Opportunities exist in agriculture, regenerative medicine, and emerging markets. The COVID-19 pandemic highlighted gene synthesis's role in vaccine development.

Editas Medicine focuses on sickle cell disease, intellectual property monetization, and in vivo pipeline advancement. Its lead candidate, reni-cel, shows promising results in treating SCD and Thalassemia. Editas faces competition from established players but aims to leverage its strong patent estate and unique up-regulation techniques. Data updates from the RUBY trial in 2024 could significantly impact its market performance.

CRISPR technology, including CRISPR-Cas9, CRISPR-Cas12, and CRISPR-Cas13, is revolutionizing genome editing. FDA approved the first CRISPR-Cas9 drug, Casgevy®, for sickle cell disease and beta thalassemia. Other applications include treating urinary tract infections, hereditary transthyretin amyloidosis, hereditary angioedema, cardiovascular diseases, type 1 diabetes, systemic lupus erythematosus, HIV, and blood cancers. Challenges include cost, regulatory standards, and ethical considerations.